NASDAQ
KA

Kineta Inc.

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Kineta Inc. Stock Price

Vitals

Today's Low:
$2.03
Today's High:
$2.1854
Open Price:
$2.05
52W Low:
$1.7799
52W High:
$15.54
Prev. Close:
$2.03
Volume:
12858

Company Statistics

Market Cap.:
$19.25 million
Book Value:
0.771
Revenue TTM:
$6.13 million
Operating Margin TTM:
-327.41%
Gross Profit TTM:
$9.09 million
Profit Margin:
0%
Return on Assets TTM:
-100.62%
Return on Equity TTM:
0%

Company Profile

Kineta Inc. had its IPO on 2016-02-11 under the ticker symbol KA.

The company operates in the Healthcare sector and Biotechnology industry. Kineta Inc. has a staff strength of 11 employees.

Stock update

Shares of Kineta Inc. opened at $2.05 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.03 - $2.19, and closed at $2.03.

This is a 0% increase from the previous day's closing price.

A total volume of 12,858 shares were traded at the close of the day’s session.

In the last one week, shares of Kineta Inc. have increased by +3.05%.

Kineta Inc.'s Key Ratios

Kineta Inc. has a market cap of $19.25 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months Kineta Inc.’s revenue was $6.13 million with a gross profit of $9.09 million and an EBITDA of $-20024000. The EBITDA ratio measures Kineta Inc.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Kineta Inc.’s operating margin was -327.41% while its return on assets stood at -100.62% with a return of equity of 0%.

In Q2, Kineta Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 519.6%.

Kineta Inc.’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-11.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Kineta Inc.’s profitability.

Kineta Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

Kineta Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$17.50 million
Total Liabilities
$9.37 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Kineta Inc. ended 2024 with $17.50 million in total assets and $0 in total liabilities. Its intangible assets were valued at $17.50 million while shareholder equity stood at $7.50 million.

Kineta Inc. ended 2024 with $0 in deferred long-term liabilities, $9.37 million in other current liabilities, 10000.00 in common stock, $-157755000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.77 million and cash and short-term investments were $7.77 million. The company’s total short-term debt was $1,321,000 while long-term debt stood at $382000.00.

Kineta Inc.’s total current assets stands at $13.02 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $5.00 million compared to accounts payable of $6.11 million and inventory worth $0.

In 2024, Kineta Inc.'s operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Kineta Inc. paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$2.03
52-Week High
$15.54
52-Week Low
$1.7799
Analyst Target Price
$10.75

Kineta Inc. stock is currently trading at $2.03 per share. It touched a 52-week high of $15.54 and a 52-week low of $15.54. Analysts tracking the stock have a 12-month average target price of $10.75.

Its 50-day moving average was $2.15 and 200-day moving average was $4.79 The short ratio stood at 1.31 indicating a short percent outstanding of 0%.

Around 3329.2% of the company’s stock are held by insiders while 341.7% are held by institutions.

Frequently Asked Questions About Kineta Inc.

The stock symbol (also called stock or share ticker) of Kineta Inc. is KA

The IPO of Kineta Inc. took place on 2016-02-11

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$97.4
-7.88
-7.48%
$118
-8.75
-6.9%
Intapp Inc (INTA)
$35.01
0.23
+0.66%
$9.86
0.06
+0.61%
$13.55
0.28
+2.11%
$253.95
-16.3
-6.03%
$54.3
-2.33
-4.11%
$9.03
-0.06
-0.66%
$159.11
-0.99
-0.62%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Kineta, Inc., a clinical-stage biotechnology company, develops immunotherapies in the field of immuno-oncology, cancer, neurology, and arenaviruses. The company is developing KVA12123, an anti-VISTA antagonist mAb immunotherapy, which is in Phase 1/2 clinical trials for the treatment of solid tumors, including non-small cell lung cancer, ovarian cancer, colorectal cancer, colon cancer, pancreatic cancer, and gastric cancer. It is also developing anti-CD27 agonist mAb immunotherapy, which is in Phase 1 clinical trials for the treatment of advanced solid tumors, such as renal cell carcinoma, ovarian cancer, and colorectal cancer. In addition, the company develops immunotherapies for pain management and anti-viral therapy for the treatment of emerging diseases. Kineta, Inc. has collaboration and license agreements with MSD International Business GmbH, and GigaGen, Inc. The company was formerly known as Lecura, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.

Address